ArticlePloS one2011
siRNA off-target effects can be reduced at concentrations that match their individual potency.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 88 citations in OpenAlex.
- Generation ofJBMR plus · 2026Article
- Myrrh ameliorates endometriosis by enhancing ER stress-related apoptotic cell death.Experimental and therapeutic medicine · 2026Article
- Potential Applications of RNase P Ribozyme Against Hepatitis B Virus.Molecules (Basel, Switzerland) · 2025Review
- RNA Interference Applied to Crustacean Aquaculture.Biomolecules · 2024Review
- Engineered zwitterionic diblock copolymer-siRNA polyplexes provide highly effective treatment of triple-negative breast cancer in a 4T1 murine model.Advanced functional materials · 2024Article
- Exploring the Potential of siRNA Delivery in Acute Myeloid Leukemia for Therapeutic Silencing.Nanomaterials (Basel, Switzerland) · 2023Article
- Antiviral and protective effect of small interfering RNAs against rift valley fever virus in vitro.Molecular biology reports · 2023Article
- Cancer Therapeutic siRNA Delivery and Imaging by Nitrogen- and Neodymium-Doped Graphene Quantum Dots.ACS biomaterials science & engineering · 2023Article
- Clinical Pharmacology of RNA Interference-Based Therapeutics: A Summary Based on Food and Drug Administration-Approved Small Interfering RNAs.Drug metabolism and disposition: the biological fate of chemicals · 2023Review
- Modulating Expression of Endogenous Interleukin 1 Beta in the Acute Phase of the Pilocarpine Model of Epilepsy May Change Animal Survival.Cellular and molecular neurobiology · 2023Article
- miR-505-5p alleviates acute rejection of liver transplantation by inhibiting Myd88 and inducing M2 polarizationof Kupffer cells.Acta biochimica et biophysica Sinica · 2022Article
- RNA-Based Therapy for Cryptosporidium parvum Infection: Proof-of-Concept Studies.Infection and immunity · 2022Article
- Long non-coding RNAs: From disease code to drug role.Acta pharmaceutica Sinica. B · 2021Review
- Transferrin-mediated iron sequestration suggests a novel therapeutic strategy for controlling Nosema disease in the honey bee, Apis mellifera.PLoS pathogens · 2021Article
- Silencing Osteopontin Expression Inhibits Proliferation, Invasion and Induce Altered Protein Expression in Melanoma Cells.Pathology oncology research : POR · 2021Article
- Long Noncoding RNAs: Novel Important Players in Adipocyte Lipid Metabolism and Derivative Diseases.Frontiers in physiology · 2021Review
- Small Interfering RNAs Are Highly Effective Inhibitors of Crimean-Congo Hemorrhagic Fever Virus Replication In Vitro.Molecules (Basel, Switzerland) · 2020Article
- Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson's disease in the precision medicine era.Medicinal research reviews · 2020Review
- Chimera RNA interference knockdown of γ-synuclein in human cortical astrocytes results in mitotic catastrophe.Neural regeneration research · 2020Article
- Biological and morphological consequences of dsRNA-induced suppression of tetraspanin mRNA in developmental stages of Echinococcus granulosus.Parasites & vectors · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small interfering RNAs (siRNAs) are routinely used to reduce mRNA levels for a specific gene with the goal of studying its function. Several studies have demonstrated that siRNAs are not always specific and can have many off-target effects. The 3' UTRs of off-target mRNAs are often enriched in sequences that are complementary to the seed-region of the siRNA. We demonstrate that siRNA off-targets can be significantly reduced when cells are treated with a dose of siRNA that is relatively low (e.g. 1 nM), but sufficient to effectively silence the intended target. The reduction in off-targets was demonstrated for both modified and unmodified siRNAs that targeted either STAT3 or hexokinase II. Low concentrations reduced silencing of transcripts with complementarity to the seed region of the siRNA. Similarly, off-targets that were not complementary to the siRNA were reduced at lower doses, including up-regulated genes that are involved in immune response. Importantly, the unintended induction of caspase activity following treatment with a siRNA that targeted hexokinase II was also shown to be a concentration-dependent off-target effect. We conclude that off-targets and their related phenotypic effects can be reduced for certain siRNA that potently silence their intended target at low concentrations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.